7 Bay Area drugs that face competition from cheaper biotech 'generics'

Call them biosimilars, copycats, generics or follow-on biologics, but the age of cheaper versions of biotech drugs is on us. Just last week, the Food and Drug Administration OK'd Zarxio — the first so-called biosimilar to win FDA approval— from Novartis AG (NYSE: NVS). Zarxio is a version of the Amgen Inc. (NASDAQ: AMGN) drug Neupogen, which increases infection-fighting white blood cell production in chemotherapy patients. See our 'generics' slideshow. >>>> At stake are tens of billions of…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news